 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Efficacy of enzalutamide combined with samotolisib in the treatment of metastatic drug-resistant prostate cancer

Clin Cancer Res: Efficacy of enzalutamide combined with samotolisib in the treatment of metastatic drug-resistant prostate cancer

 Last Update: 2022-08-12
 Source: Internet
 Author: User

Tags

bed study

drought resistant crops

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Prostate cancer is one of the most common cancers in men worldwi.

The PI3K/protein kinase B/mTOR (PI3K/AKT/mTOR) signaling pathway is one of the most frequently activated signaling pathways in solid and hematological malignanci.

Preclinical studies have shown that the PI3K/AKT/mTOR signaling pathway is potentially associated with the androgen receptor (AR) signaling axis in ADT-resistant prostate cancer cel.

This study aimed to evaluate the efficacy and safety of samotolisib, a dual PI3K/mTOR kinase and DNA-dependent protein kinase inhibitor, combined with enzalutamide in patients with mCR.

The primary endpoint was progression-free surviv.

Median PFS and rPFS were significantly longer in both the samotolisib/enzalutamide group compared with the placebo/enzalutamide group (8 vs 8 months, p=003; 12 vs 5 months, p=03.

In conclusion, samotolisib/enzalutamide significantly improved progression-free survival in patients with metastatic-resistant prostate cancer that had progressed on abiraterone, was well tolerated , and was free of androgen receptor splice variantPatients benefit more significant.

Samotolisib/enzalutamide significantly improves progression-free survival in patients with metastatic drug-resistant prostate cancer that has progressed on abiraterone, and is well tolerated Samotolisib/enzalutamide significantly improves abiraterone therapy Progression-free survival in patients with metastatic drug-resistant prostate cancer that progresses and is well tolerated

Original source:

Christopher.

Christopher.
Sweeney, et .
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Canc.
Clin Cancer Res OF1–OF1 https://d.
org/11158/1078 -043CCR-21-232 Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

High Quality Resveratrol 99% powder 501-36-0 Shaanxi Dideu Medichem Co.Ltd

CAS No.: 501-36-0

Chemical Grade

$1/KG FOB

High purity Epirubicin hydrochloride 98% with best price 56390-09-1 and Epirubicin hydrochloride raw powder

CAS No.: 56390-09-1

Pharmacy Grade

$8.8-10/MT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.